abs150.txt	background		although	induction	studies	of	tpf	in	scchn	have	not	improved	outcomescompared	to	chemoradiotherapy	alone		phase	ii	studies	of	weekly	carboplatin(cbp)		paclitaxel	and	cetuximab	(c225)	have	shown	promising	results	nano-albumin-paclitaxel	(nab-paclitaxel)	based	chemotherapy	has	demonstrated	ahigher	response	rate	(rr)	than	solvent-based	paclitaxel	in	squamous	cellcarcinoma	of	the	lung	with	favorable	toxicity	materials	and	methods		patients	with	treatment	naïve	scchn	of	any	site	with	≥n2bdisease	or	that	was	unresectable	by	strict	criteria	were	eligible		patients	weretreated	with	nab-paclitaxel	100	mg/m2		cbp	area	under	the	curve	(auc)	2	and	c225400	mg/m2	week	1	then	250	mg/m2	for	six	weeks		followed	by	standard	of	carechemoradiotherapy	(crt)		the	primary	endpoint	was	clinical	response	rate	toinduction	therapy	as	defined	by	recist	version	1	1		secondary	measures	includedtoxicity		progression-free	survival		overall	survival	and	quality	of	life	asmeasured	by	fact-hn	results		38	eligible	subjects	were	treated		primary	sites	were		oropharynx	(opx)(25)		larynx	(3)	oral	cavity	(oc)	(9)		hypopharynx	(1)		the	most	common	grade	3or	4	toxicity	during	induction	was	acneiform	rash	(26%)	followed	by	neutropenia(16%)		rr	was	76	3%		median	pfs	and	os	have	not	been	reached	(median	follow-up	of3	3	years)		they	were	superior	in	patients	with	response	conclusions		the	combination	of	nab-paclitaxel		cbp	and	c225	is	feasible	tolerable	and	active	against	locally	advanced	scchn	
